Your browser doesn't support javascript.
loading
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Mehanna, Hisham; Robinson, Max; Hartley, Andrew; Kong, Anthony; Foran, Bernadette; Fulton-Lieuw, Tessa; Dalby, Matthew; Mistry, Pankaj; Sen, Mehmet; O'Toole, Lorcan; Al Booz, Hoda; Dyker, Karen; Moleron, Rafael; Whitaker, Stephen; Brennan, Sinead; Cook, Audrey; Griffin, Matthew; Aynsley, Eleanor; Rolles, Martin; De Winton, Emma; Chan, Andrew; Srinivasan, Devraj; Nixon, Ioanna; Grumett, Joanne; Leemans, C René; Buter, Jan; Henderson, Julia; Harrington, Kevin; McConkey, Christopher; Gray, Alastair; Dunn, Janet.
Affiliation
  • Mehanna H; Institute for Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK. Electronic address: h.mehanna@bham.ac.uk.
  • Robinson M; Newcastle University, Newcastle, UK.
  • Hartley A; University Hospitals Birmingham, Birmingham, UK.
  • Kong A; Institute for Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
  • Foran B; Weston Park Hospital, Sheffield, UK.
  • Fulton-Lieuw T; Institute for Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.
  • Dalby M; University of Warwick, Coventry, UK.
  • Mistry P; University of Warwick, Coventry, UK.
  • Sen M; St James's Institute of Oncology, Leeds, UK.
  • O'Toole L; Queen's Centre for Oncology, Castle Hill Hospital, Cottingham, UK.
  • Al Booz H; Bristol Haematology and Oncology Centre, Bristol, UK.
  • Dyker K; St James' University Hospital, Leeds, UK.
  • Moleron R; Aberdeen Royal Infirmary, Aberdeen, UK.
  • Whitaker S; Royal Surrey County Hospital, Surrey, UK.
  • Brennan S; St Luke's Hospital, Cancer Trials Ireland, and St Luke's Institute of Cancer Research, Dublin, Ireland.
  • Cook A; Cheltenham General Hospital, Cheltenham, UK.
  • Griffin M; Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Aynsley E; James Cook University Hospital, Middlesbrough, UK.
  • Rolles M; Abertawe Bro Morgannwg University Health Board, Port Talbot, UK.
  • De Winton E; Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.
  • Chan A; University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK.
  • Srinivasan D; Western General Hospital, Edinburgh, UK.
  • Nixon I; Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Grumett J; University of Warwick, Coventry, UK.
  • Leemans CR; VU University Medical Centre, Amsterdam, Netherlands.
  • Buter J; VU University Medical Centre, Amsterdam, Netherlands.
  • Henderson J; National RTTQA Group, Royal Marsden Hospital, London, UK.
  • Harrington K; Institute of Cancer Research and Royal Marsden Hospital, London UK.
  • McConkey C; University of Warwick, Coventry, UK.
  • Gray A; University of Oxford, Oxford, UK.
  • Dunn J; University of Warwick, Coventry, UK.
Lancet ; 393(10166): 51-60, 2019 01 05.
Article in En | MEDLINE | ID: mdl-30449623
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oropharyngeal Neoplasms / Cisplatin / Cetuximab / Squamous Cell Carcinoma of Head and Neck / Antineoplastic Agents Type of study: Clinical_trials / Etiology_studies / Guideline / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Lancet Year: 2019 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oropharyngeal Neoplasms / Cisplatin / Cetuximab / Squamous Cell Carcinoma of Head and Neck / Antineoplastic Agents Type of study: Clinical_trials / Etiology_studies / Guideline / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Lancet Year: 2019 Type: Article